| 0.7625 0.064 (9.08%) | 03-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.02 | 1-year : | 1.19 |
| Resists | First : | 0.87 | Second : | 1.02 |
| Pivot price | 0.7 |
|||
| Supports | First : | 0.55 | Second : | 0.36 |
| MAs | MA(5) : | 0.69 |
MA(20) : | 0.69 |
| MA(100) : | 0.71  |
MA(250) : | 1.11 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.1 |
D(3) : | 56 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 1.9 | Low : | 0.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ COCH ] has closed above the upper band by 2.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 56.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.77 - 0.77 | 0.77 - 0.78 |
| Low: | 0.67 - 0.67 | 0.67 - 0.67 |
| Close: | 0.76 - 0.76 | 0.76 - 0.77 |
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices; and Acclaim cochlear implants. Envoy Medical Corporation was formerly known as St. Croix Medical, Inc. and changed its name to Envoy Medical Corporation in December 2004. The company was founded in 1995 and is based in White Bear Lake, Minnesota.
Wed, 11 Mar 2026
First fully implanted cochlear implant trial hits key U.S. milestone - Stock Titan
Wed, 11 Mar 2026
EXCLUSIVE: Envoy Medical Hits Trial Milestone For Cochlear Implant Designed To Work With Natural Ear - Benzinga
Tue, 24 Feb 2026
Envoy Medical (COCH) Price Target Increased by 15.15% to 9.69 - Nasdaq
Mon, 23 Feb 2026
Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space - TMX Newsfile
Thu, 19 Feb 2026
Fully implanted cochlear implant nears trial end as Envoy's $30M financing lands - Stock Titan
Thu, 19 Feb 2026
Glen Taylor Buys 241% More Envoy Medical Shares - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 1.714e+007 (%) |
| Held by Institutions | 36.8 (%) |
| Shares Short | 475 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.016e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 590.4 % |
| Return on Equity (ttm) | -145.4 % |
| Qtrly Rev. Growth | 208000 % |
| Gross Profit (p.s.) | -12.14 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -297087 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.91 |
| Dividend | 0 |
| Forward Dividend | 1.23e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|